Itanapraced - CereSpir

Drug Profile

Itanapraced - CereSpir

Alternative Names: CHF-5074; CSP-1103

Latest Information Update: 21 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiesi
  • Class Antidementias; Biphenyl compounds; Cyclopropanes; Propionic acids; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Glial cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mild cognitive impairment

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 21 Mar 2016 CHF 5074 is still in phase II for Mild cognitive impairment due to Alzheimer’s disease in Italy and USA
  • 14 Jul 2015 CereSpir has patent protection for CHF 5074 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top